The p53 protein plays a pivotal role in activating and integrating adaptive cellular responses to a wide range of environmental stresses. Activation of p53 can occur by dierent molecular routes, depending on the nature of the activating signal. Central to the activation process, by whichever route, is the destabilization of the p53-MDM2 interaction. The molecular mechanisms which activate p53 involve elements of post-translational modi®cation, protein stabilization and protein-protein interaction. Two central themes are emerging from recent work in this area. The ®rst is that there are common events in the p53 activation process among dierent activating pathways. The second is that activation involves not just a single molecular event such as disruption of the p53-MDM2 interaction, but a series of sequential events the nature of which is governed by the type of activating stimulus. This review summarizes our current knowledge of the p53 activation process in response to two stimuli, DNA damage and activated oncogenes, and considers the contribution made by multisite phosphorylation in determining the nature of the p53 response.
Introduction
The p53 tumour suppressor protein is a short-lived, latent transcription factor which is activated and stabilized in response to a wide range of cellular stresses including DNA damage, mitotic spindle damage and activated oncogenes (for recent reviews see Agarwal et al., 1998; Prives and Hall, 1999) . Activated p53 acts as a checkpoint which coordinates a shift in the pattern of gene expression involving the induction of genes which promote growth arrest or apoptosis and the repression of genes which stimulate growth or block apoptosis. In laboratory animals, the absence of p53 permits the occurrence of numerous genetic alterations, including gene ampli®cation and abnormal chromosome numbers, and leads to the development of a variety of tumours in young adults (Donehower et al., 1992; Fukasawa et al., 1997; Livinstone et al., 1992; Yin et al., 1992) . These ®ndings underscore the pivotal nature of p53 in preventing tumour development and are consistent with the well established occurrence of loss of p53 function in the development of a wide range of human tumours (Hollstein et al., 1996) .
At the protein level the regulation of p53 is complex and involves interdependent control by protein-protein association, protein turnover and post-translational modi®cation. The precise molecular events which are responsible for, or accompany, the activation of p53 vary according to the type of stimulus but there are clear overlapping elements within these regulatory mechanisms. Central to the regulation of p53 is its interaction with the MDM2 protein which blocks p53 transactivation function by binding to a region of the transactivation domain (Oliner et al., 1993; Zauberman et al., 1993) and mediates rapid turnover of p53 by targeting it to the 26S proteosome through a mechanism involving MDM2-mediated ubiquitination of p53 (Haupt et al., 1997; Honda and Yasuda, 1999; Kubbutat et al., 1997) . In addition to this dual role in regulating p53, the MDM2 gene is itself stimulated by p53-dependent transactivation Juven et al., 1993; Zauberman et al., 1995) . Consequently MDM2 participates in a negative regulatory loop which keeps p53 under tight control under normal conditions of cell maintenance (Wu et al., 1993) . These ®ndings suggest that MDM2 is pivotal to the regulation of p53 function.
The precise mechanisms by which p53 responds to dierent external in¯uences are not fully understood. However, the past two years have seen a number of exciting developments in our understanding of the mechanisms which activate p53 and which ®ne-tune its function. These advances have been made through the convergence of essentially two lines of research, the study of p53 stimulation by DNA damage and the analysis of p53 activation by dominant oncogenes. Central to both of these events is MDM2. The new information gained from these studies has provided a clearer understanding of the molecular events involved in switching on and controlling p53 activity and has modi®ed previous views of the role of post-translational modi®cation in these processes. There are several recent reviews which explore comprehensively the nature of the post-translational modi®cations of the p53 protein and its induction by a range of dierent cellular stresses (Giaccia and Kastan, 1998; Meek, 1997 Meek, , 1998 Prives and Hall, 1999) . The purpose of the present review therefore is to describe current perception of the mechanisms of induction and activation of p53 and to consider the signi®cance of the contribution made by post-translational modification of p53 to these events.
Activation of p53 in response to DNA damage
A number of recent studies have demonstrated that multisite phosphorylation and acetylation are key events in the activation of p53 in response to DNA damage. Much of the information gained has relied on the powerful approach of measuring modi®cation status using antibodies which recognise a given phosphorylation or acetylation site only in its phosphorylated or acetylated form respectively. The sensitivity of this method, coupled with the ability to analyse speci®c modi®cations temporally and with simplicity (by the route of Western analyses), have led to a quantum leap in our understanding of processes involved in inducing p53.
A description of the activation of p53 by DNA damage is shown schematically in Figure 1 . Shieh et al. (1997) and Siciliano et al. (1997) were the ®rst to demonstrate that de novo phosphorylation of human p53 occurs at serine 15 in response to ionising radiation (IR), DNA damage-inducing drugs and UV. Phosphopeptide mapping indicated that phosphorylation events additional to serine 15 modi®cation also occurred at the N-terminus of p53 (Siliciano et al., 1997) . Using the phospho-speci®c antibody approach, this has been con®rmed and extended by recent work from a number of laboratories and it is now clear that the activation response also includes phosphorylation at serines 20, 33 and 37 (Banin et al., 1998; Canman et al., 1998; Sakaguchi et al., 1998; Shieh et al., 1999) . The serine 15 phosphorylation site is juxtaposed to the MDM2 binding site (residues 18 ± 23) and it has been proposed that phosphorylation of p53 at serines 15 and 37 can block its interaction with MDM2 in vitro (PiseMasison et al., 1998; Shieh et al., 1997) . The consequence of disrupting the p53-MDM2 complex is the release of p53 from inhibition of transactivation and the prevention of further proteosome-mediated p53 degradation. (Subsequent p53-dependent induction of the MDM2 gene leads to a lagging accumulation of MDM2 which is thought to be part of the mechanism of recovery from the damage response.) An attractive quality of this model is that it explains how p53 could be both induced and activated simultaneously. However, although phosphorylation of serines 15 and 37 occurs in cells in response to DNA damage, the dependence of dissociation of the p53-MDM2 complex on these phosphorylation events in vivo is uncertain (see the ®nal section of this review). Moreover, other groups have found that phosphorylation of serines 15 and 37 in vitro has only a weak eect on MDM2 binding in vitro (Mayo et al., 1997; N Dumaz and D Meek, submitted) and consequently the extent to which serines 15 and 37 phosphorylation contribute to MDM2 dissociation is not fully understood. Other proposed functions for serine 15 P P P P P P P P Figure 1 Post-translational modi®cation and activation of p53 in response to DNA damage. The cartoon depicts the human p53 protein with its functional domains. The MDM2 and p300/CBP/PCAF proteins are also represented. The series of events in the activation process are indicated by the white numbers in the black square boxes and correspond to the following description of events.
(1) Protein kinase activity(ies) stimulated by DNA damage phosphorylate serine 15 (and possibly serine 37). Phosphorylation of serines 20, 33 and possibly threonine 18 is catalyzed by dierent protein kinases either simultaneously, or sequentially with serine 15 phosphorylation being the key initiating event. (2) The MDM2 protein dissociates from p53. Note that it is not yet entirely clear whether phosphorylation disrupts the MDM2-p53 complex or whether disruption is mediated by a separate event followed by the subsequent phosphorylation of p53 to prevent reformation of the complex. (3) N-terminal phosphorylation permits recruitment of key transcription factors including p300/CBP and PCAF. (4) These proteins in turn are able to acetylate residues at the C-terminus of p53 leading to stimulation of the site-speci®c DNA binding function. (5) Dephosphorylation of a key C-terminal phosphorylation site is also induced permitting binding of 14-3-3 adaptor proteins and additionally enhancing the site-speci®c DNA binding function. Note that when p53 is induced by UV as opposed to IR, there is prolonged phosphorylation of serine 37 while acetylation of lysine 320 occurs early with UV but only after 24 h with IR. UV-induced phosphorylation of serine 392 is signi®cant, but this residue is not modi®ed in response to IR phosphorylation include MDM2-independent stimulation of the transactivation function of p53 (N Dumaz and D Meek, submitted), binding to the transcription factor CBP/p300 (Lambert et al., 1998) and regulation of the interaction of p53 with the TFIID transcription factor; in the latter case phosphorylation of serine 15 alone blocks binding to TFIID whereas dual phosphorylation of serines 15 and 37 stimulate this interaction (Pise-Masison et al., 1998) . Bearing in mind that enzymes such as the ATM kinase phosphorylate serine 15 alone (Banin et al., 1998) whereas DNA-PK and ATR phosphorylate both serines 15 and 37 (Lees et al., 1992; Tibbetts et al., 1999) , the way in which p53 interacts with TFIID may depend upon both the initiating signal and its timing. Based on current evidence, serine 15 phosphorylation has pleiotropic eects on p53 activity, which may cooperate with other modi®cations of p53. Both serine 20 phosphorylation and threonine 18 phosphorylation (which has yet to be shown to occur in vivo) have been demonstrated to weaken signi®cantly the interaction of p53 with MDM2 in vitro (Bottger et al., 1999; Unger et al., 1999) . Moreover, loss of serine 20 makes p53 more susceptible to MDM2 inhibition as measured by p53 transactivation and apoptosis functions (Unger et al., 1999) , providing biological data which supports the model.
In addition to the N-terminal phosphorylation, modi®cations also occur at the C-terminus. Waterman et al. (1998) reported that serines 376 and 378 are normally phosphorylated in unstimulated cells and that IR induces rapid dephosphorylation of serine 376. This change in modi®cation status unmasks a site to which 14-3-3 adaptor proteins can bind, leading to stimulation of the site-speci®c DNA binding function of p53. p53 is also acetylated at C-terminal lysine residues 320 by PCAF and at 373 and/or 382 by p300/CBP, in response to both IR and UV (Gu and Roeder, 1997; Liu et al., 1999; Sakaguchi et al., 1998) . Again the sequence speci®c DNA binding function of p53 is activated by these modi®cations either by inducing a conformational change or, based on the`reciprocal interference' model described by Anderson et al. (1997) , by blocking the non-speci®c DNA binding function of the protein . One striking aspect of these studies is that phosphorylation of serines 15 (Lambert et al., 1998) or 33 and 37 ) is thought to enhance recruitment of the p300 and PCAF acetylases to p53, leading to enhanced acetylation of the C-terminus of p53. While there are dierences of opinion as to the precise residues involved in this process, the link between N-and C-terminal modi®cation, in particular the dependence of acetylation on prior N-terminal phosphorylation, suggests strongly that the DNA damage-induced modi®cations of p53 are not a disparate group of events but a carefully coordinated and sequential series of changes which favour dissociation of the p53-MDM2 complex, recruitment of key transcriptional components to p53, and activation of the site-speci®c DNA binding function of the protein. This idea also suggests that release from MDM2 binding and stabilization of p53 is not the sole means of inducing p53 function by DNA damage but favours the conclusion by other researchers that stabilization and activation by covalent modi®cation are separate but cooperating events .
Protein kinase activities involved in phosphorylating p53 in response to DNA damage
The N-terminus of p53 is phosphorylated in vitro by (at least) three dierent DNA damage-responsive protein kinase activities, each of which belongs to the PI-3-kinase family. These are the DNA activated protein kinase (DNA-PK); the ATM kinase, the product of the ATM gene which is mutated in the genetic disorder ataxia telangiectasia (AT); and the ATR kinase (ATMRad3-related). DNA-PK phosphorylates human p53 at serines 15 and 37 in vitro and is dependent for activity on interaction with double-stranded DNA structures containing nicks or gaps (Anderson, 1994; Jackson and Jeggo, 1995) . The kinase comprises a 460 kD catalytic subunit (with homology to the PI-3-kinase family) and a dimeric targeting factor termed Ku which binds to duplex DNA ends and recruits the catalytic subunit to the DNA. Initially, the interaction between p53 and DNA-PK had aroused much excitement based on the idea that a signalling pathway might exist in which DNA-PK recognized strand breaks directly, leading to its activation and subsequent phosphorylation of p53. However, while DNA-PK phosphorylates residues in p53 in vitro which are implicated in the DNA damage response in vivo, several reports dismissed any physiological interaction of DNA-PK and p53 on the basis that p53 could still be induced by IR in cells from severe combined immunode®cient (SCID) mice (Fried et al., 1996; Guidos et al., 1996; Jongmans et al., 1996; Nacht et al., 1996; Rathmell et al., 1997) ; (these mice carry a mutation in the DNA-PK catalytic subunit which is thought to be the molecular defect underlying the SCID phenotype). Recently, however, Woo et al. (1998) questioned the penetrance of the SCID mutation, arguing that SCID cells retain detectable and signi®cant levels of DNA-PK protein kinase activity. They showed that p53 could not be activated in cell lines lacking any detectable DNA-PK activity and provided striking evidence that catalytically active DNA-PK is required, in conjunction with an as yet unde®ned nuclear factor, for DNA damage-induced sequence-speci®c DNA binding of p53. Interestingly, this study showed that the p53 protein can still be induced in the absence of DNA-PK, but that the basal p53 level is higher in the DNA-PK-null background. Consistent with this report, Abraham et al. (1999) showed that the level of p53 was dependent on DNA-PK (catalytic subunit) gene dosage, with the highest level of p53 observed in cells lacking functional DNA-PK. Therefore, while these eects are not yet understood, there is a clear suggestion that DNA-PK plays a role in de®ning the level of p53 in the cell.
A prime candidate for the protein kinase which activates p53 in response to IR is the product of the ATM gene. AT patients show pleiotropic phenotypes including hypersensitivity to IR and predisposition to cancer. ATM had long been suspected of being an upstream component of the p53 pathway on the basis that the induction of p53 in cells from AT patients showed a signi®cant delay in the response to IR (Kastan et al., 1992; Khanna and Lavin, 1993) . Recently ATM was shown to be a bona ®de protein kinase which can phosphorylate p53 at serine 15 in vitro (Banin et al., 1998; Canman et al., 1998; Khanna et al., 1998) . Moreover, several lines of evidence supported the idea that ATM was indeed immediately upstream of p53 in the pathway responding to IR and radiomimetic drugs: (1) serine 15 phosphorylation correlates with stimulation of ATM protein kinase activity in cultured cells (Banin et al., 1998; Canman et al., 1998) ; (2) ATM physically complexes with p53 in cells from normal individuals but this is defective in AT cells (Khanna et al., 1998; Watters et al., 1997) ; (3) serine 15 phosphorylation is severely delayed in AT cells (Canman et al., 1998) ; and (4) ectopic expression of ATM in AT cells restores IR-induced phosphorylation of p53 at serine 15 whereas expression of antisense RNA in normal cells abrogates serine 15 phosphorylation (Khanna et al., 1998) . In addition to its role in phosphorylating serine 15, the ATM protein kinase has also been implicated in the pathway which leads to dephosphorylation of serine 376 on the basis that IRinduced dephosphorylation of this residue is defective in AT cells. It has been proposed that its action here may occur through regulation of a p53 phosphatase (Waterman et al., 1998) . The picture emerging from these studies is that ATM plays a dual role in activating p53 through phosphorylation of serine 15 and dissociation of MDM2 at the N-terminus coupled with dephosphorylation and 14-3-3 binding at the Cterminus.
The third PI-3-kinase member implicated in the induction of p53 is the ATR kinase. ATR is structurally related to ATM and can phosphorylate both serine 15 and serine 37 of human p53 in vitro, albeit with 20-fold lower activity as compared with ATM under the same conditions (Canman et al., 1998; Tibbetts et al., 1999) . ATR has been proposed to have overlapping function with ATM on the basis that kinase-inactive mutants of ATR cause hypersensitivity to g or x-radiation and hydroxyurea, and abrogate radiation-induced checkpoint control (Cliby et al., 1998; Wright et al., 1998) . Analyses with kinase-dead mutants also revealed that ATR can block the maintenance, but not the initiation, of serine 15 phosphorylation in response to IR, suggesting that ATM and ATR act sequentially in the DNA damage response (Tibbetts et al., 1999) . Tibbetts et al. also suggested that ATR might provide the basis for the ®nding that DNA-damaged AT cells show a delay in p53 induction and phosphorylation of serine 15, but not a complete loss of the response. Perhaps the most striking observation concerning the role of ATR as an upstream component in the p53 pathway is that it plays a central role in the activation of p53 by UV (Tibbetts et al., 1999) .
As discussed above, there are several other phosphorylation sites modi®ed during the induction of p53 by DNA damage. While recent progress has provided strong evidence for the role of ATM and ATR in the induction process, little is known at present concerning the protein kinase or phosphatase activities which modify these other sites during the response. For example, although in vitro evidence suggests a possible role for threonine 18 in regulating MDM2 binding (Bottger et al., 1999) , a threonine 18 kinase has not yet been reported. Similarly the protein kinase which phosphorylates serine 20 is unknown. However, serine 33 of human p53 has been proposed to be an in vitro target for the CDK7-cyclin H-p36 protein kinase which is a component of the repair-associated transcription factor TFIIH (Ko et al., 1997) ; (interestingly, this enzyme has also been shown to phosphorylate serines 371, 376 and 378 within the PAb421 epitope (Lu et al., 1997) . The proposed mechanism by which DNA damage leads to phosphorylation by CDK7-cyclin Hp36 involves binding of TFIIH to RNA polymerase-DNA complexes which have paused at sites of DNA damage. Recruitment of p53 to these sites through its ability to recognize and bind to damaged DNA would put p53 and the kinase in very close proximity. Phosphorylation of p53 could then occur allowing the p53 to dissociate in an activated form and switch on gene expression (Ko et al., 1997; Lu et al., 1997) .
In murine p53 the site equivalent to the human serine 33 is serine 34. This residue has been shown to be physiological target for JNK1-3, members of the stress-activated family of protein kinases, and can be phosphorylated in cultured cells in response to UV irradiation under conditions which lead to the activation of JNK (Hu et al., 1997; Milne et al., 1995) . (It is possible that two dierent pathways involving JNK and TFIIH respectively could target this residue independently.) Recent evidence (Fuchs et al., 1998a,b) has suggested that JNK forms stable complexes with p53 through its interaction with a docking site contained within amino acids 97-116. Based on comparison with other JNK substrates, it is proposed that p53 is normally targeted by JNK for degradation through formation of this complex. Upon cellular stress however, JNK becomes activated and phosphorylates p53 resulting not only in disruption of the p53-JNK complex but also in preventing the association of p53 with MDM2. Thus, there are apparently two independent but overlapping mechanisms through which p53 can be eliminated, both of which involve protein-protein associations which can be disrupted by phosphorylation mechanisms.
Finally, phosphorylation in vitro of residues within the PAb421 epitope at the C-terminus has been attributed to protein kinase C (Baudier et al., 1992; Hupp and Lane, 1994; Milne et al., 1996; Takenaka et al., 1995) , protein kinase A (Waterman et al., 1998) and CDK7-cyclin H-p36 (Lu et al., 1997) but again it is not clear whether either or all of these enzymes can phosphorylate these sites in vivo. Similarly, the identity of the ATM dependent protein phosphatase which dephosphorylates serine 376 is not known.
Induction of p53 by UV: variations on a theme
The induction of p53 by agents which cause strand breaks, such as IR, has long been known to occur through a dierent route from UV light which causes pyrimidine dimers and generates oxidative eects. These ®ndings ®rst came to light from the study of cells from AT patients which showed uncoupling of the IR and UV responses (Khanna and Lavin, 1993) . New evidence is beginning to highlight both similarities and dierences in the modi®cation status and signalling components which target p53 in response to these dierent stimuli. As with agents which cause double strand breaks, UV irradiation of cells also leads to phosphorylation of serine 15 but the kinetics of UV-induced serine 15 phosphorylation are much slower as compared with the IR response Siliciano et al., 1997; Tibbetts et al., 1999) , suggesting that the serine 15 kinase is activated by a slower route or that a dierent protein kinase from ATM targets this residue in response to UV. Several lines of evidence argue ®rmly that ATR and not ATM is the principal UV responsive serine 15 kinase: (1) phosphorylation of p53 at serine 15 by UV is unaected in AT cells (Siliciano et al., 1997) ; (2) the UV response is blocked by expression of a dominantnegative mutant of ATR (Tibbetts et al., 1999) ; and (3) ATM protein kinase activity is not stimulated signi®cantly by UV (Canman et al., 1998) . Moreover, the enhanced phosphorylation of serine 37 by UV as compared with IR is consistent with a major role for ATR after UV-induction .
Similar to the eect with IR, serines 20 and 33 are phosphorylated in response to UV, but the kinetics of these modi®cations are slower and there is a signi®cant lag in the serine 20 phosphorylation . These data are consistent with the phosphorylation of the N-terminal residues being sequential in nature. There are also dierences in acetylation in comparing UV with IR, and while both lysine 320 and lysine 382 are acetylated by both pathways, lysine 320 acetylation is an early event following UV but late with IR . Perhaps the singular most striking modi®cation which distinguishes the strand break and UV responses is the phosphorylation of serine 392; (serine 386 in murine p53). Several groups have now shown that phosphorylation of this site is induced by UV but not by g-radiation or etoposide (Blaydes and Hupp, 1998; Kapoor and Lozano, 1998; Lu et al., 1998) . Phosphorylation of this site has been attributed to casein kinase 2 (CK2) (Meek et al., 1990) and its modi®cation activates a number of functions encompassed within the p53 protein (discussed in Meek, 1997 Meek, , 1998 including site-speci®c DNA binding (Hupp et al., 1992) and, consequently, transactivation (Hao et al., 1996; Mundt et al., 1997) . It has also been suggested that a 5,6 dichloro-1-b-D-ribofuranosylbenzimidazole (DRB)-resistant protein kinase distinct from CK2 may additionally phosphorylate this site (Blaydes and Hupp, 1998) ; (DRB is a speci®c inhibitor of CK2).
It is not clear at present why the variations exist in the modi®cation status of p53 following strand breaks as compared with UV. Double-stranded breaks are repaired by ligation and recombination whereas UV light produces pyrimidine dimers which are mended by excision repair. One possibility is that these dierences in modi®cation alert p53 to the type of damage that has occurred and in¯uence subtly the nature of the p53 response, for example in ®ne-tuning the p53-dependent shift in the balance of gene expression in a manner which favours the appropriate means of damage repair. This is an attractive hypothesis which remains to be tested.
Induction of p53 by dominant oncogenes: an alternative route p53 can also be induced through the action of dominant oncogene products which drive sustained and unrestricted cell growth (Figure 2 ). This induction is dependent on a product of the INK4A tumour suppressor gene which encodes two unrelated proteins, p16 INK4A and p19 ARF (murine protein) or p14 ARF (human protein) (Quelle et al., 1995; Serrano et al., 1993) . Disruption or mutations in these overlapping genes are common events in human cancer, second only to p53 mutation. p16
INK4A restrains growth by inhibiting the activity of cyclin D/CDK4 and 7CDK6, thus preventing phosphorylation of RB and inhibiting S phase entry. Clues as to the function of the ARF protein came from dierent directions. Firstly yeast two hybrid analysis revealed that MDM2 was an interacting partner for p14 ARF (Zhang et al., 1998) , suggesting the possibility that ARF might be a regulator of MDM2 and consequently of p53. Other evidence came from the ®nding that p19 ARF could induce cell cycle arrest that was dependent on p53 (Quelle et al., 1995) , and from the observation that post-crisis ARF-null cells retained functional p53 (Kamijo et al., 1997) . These studies led various groups to analyse the relationship between p53, MDM2 and ARF.
Several laboratories have now shown that ARF binds to a C-terminal region in the MDM2 protein and that ARF, MDM2 and p53 can exist as a ternary complex with MDM2 being the linking molecule Pomerantz et al., 1998; Stott et al., 1998; Zhang et al., 1998) . The interaction of ARF with MDM2 abrogates the ability of MDM2 to block the transactivation function of p53 and interferes with MDM2-mediated p53 degradation Pomerantz et al., 1998; Stott et al., 1998; Zhang et al., 1998) . Thus ARF expression leads to the stabilization of p53 by a mechanism which may involve increased turnover of MDM2 itself (Zhang et al., 1998) and/or inactivation of the intrinsic ubiquitin ligase activity of MDM2 for p53 (Honda and Yasuda, 1999) . These ). ARF binds to MDM2 and blocks its ability to negatively regulate p53 and promote its degradation. p53 accumulates and can mediate downstream eects of growth restraint. The induction of ARF is independent of the induction of p53 by DNA damage but can cooperate with this pathway. Arrows at the end of lines indicate stimulatory eects whereas bars indicate inhibitory eects increased levels of p53 are re¯ected in the induction of p53-dependent transcription, growth arrest, apoptosis and suppression of oncogenic transformation (Pomerantz et al., 1998; Stott et al., 1998; Zhang et al., 1998) . Moreover, ARF cannot mediate its eects in the absence of functional p53, con®rming that p53 and ARF lie adjacent in the pathway. p53 can also downregulate ARF , suggesting that these two proteins operate in a negative feedback loop not unlike the p53-MDM2 loop.
Induced expression of ARF is the means by which dominant oncogenes induce p53. Myc selectively induces ARF mRNA expression (without aecting p16 mRNA levels), giving rise to up to tenfold increases in p53 levels . Similarly, E1A can also induce expression of ARF mRNA and protein, by a dual mechanism which involves inactivating the RB protein (thereby releasing functional E2F-1) and binding to p300/CBP (de Stanchina et al., 1998) . The central role of ARF in inducing p53 by dominant oncogenes is underscored by the ®nding, in these studies, that oncogenes are unable to induce p53 and its downstream responses in ARF-null cells, while reintroduction of ARF restores oncogene responsiveness. Both p16
INK4A and ARF are essential for the activation of p53 and p53-dependent premature senescence in response to activated Ras or constitutively active MEK (MAP and ERK kinase, a downstream component of the MAP kinase pathway) (Lin et al., 1998; Palmero et al., 1998) . Ras promotes uncontrolled proliferation and transformation in cells lacking either p53 or p16
INK4A
, underscoring the involvement of both products of the INK4A gene in Ras responsiveness. The ability of oncogenes to elicit a p53 response is independent of the DNA damageinduced p53 pathway. For example, cells treated with actinomycin D show p53 induction but without any detectable change in ARF levels (Stott et al., 1998) . Similarly, E1A can induce p53 without any detectable phosphorylation of serine 15 (de Stanchina et al., 1998) . Moreover, ionising radiation can induce serine 15 phosphorylation without further increases in p53 levels in cells expressing E1A and the ®nding that overexpression of ARF can further enhance apoptosis induced by adriamycin suggests that these two independent pathways can act synergistically (de Stanchina et al., 1998) .
ARF therefore provides a mechanism that is independent of the DNA damage-induced p53 pathway, by which inappropriate growth signals are countered by instituting a p53-dependent growth restraint. Thus, when the p53`pathway' is functional, oncogene expression leads to apoptosis or premature senescence through the activation of p53. When the p53 pathway is inoperative, for example when ARF or p53 are mutated or in the presence of viral oncoproteins which ablate p53 function (such as SV40 T antigen or papillomavirus E6 protein) oncogene-driven growth transformation persists unchecked.
Species-dependent dierences in post-translational modi®cation
The advent of antibodies which can discriminate on the basis of the presence or absence of a modi®cation have permitted striking advances in our detailed knowledge of the modi®cations which occur in human p53. Until recently, murine p53 was perhaps the most well characterized in terms of its phosphorylation (Meek, 1997) . On the basis of what was then known, it appeared that phosphorylation of p53 from humans, mice and other species showed considerable similarity. Recently, however, there has been growing evidence suggesting that there may be signi®cant species-dependent dierences in the way in which p53 is modi®ed and regulated. There are several examples of such dierences and these are shown schematically in Figure 3. (1) Murine p53 is a good substrate in vitro for the mitogen-activated protein kinases ERK1 and ERK2 which phosphorylate two residues in the polyproline domain (Milne et al., 1994) . Activation of the MAP kinase pathway in cultured cells leads to speci®c phosphorylation of the polyproline domain, suggesting that this modi®cation is physiologically signi®cant (Milne et al., 1994 (Milne et al., , 1996 . Human p53, however, is not a substrate for MAP kinase nor does activation of MAP kinase in human cells aect the modi®cation status of p53 (L Jardine, D Milne and D Meek, submitted) . (2) DNA-activated protein kinase phosphorylates both human and murine p53 at serine 15 but human p53 is additionally phosphorylated at serine 37 (a site not present in murine p53) while murine p53 is phosphorylated at a dierent additional site, serine 4 (a site absent from human p53) (Lees et al., 1992; Lees-Miller et al., 1990) . (3) Human p53 is phosphorylated in vivo within the epitope for monoclonal antibody PAb421 (Waterman et al., 1998) but mutation of the homologous residues in murine p53 does not aect the phosphorylation status of the protein in vivo (Milne et al., 1996) . (4) Phosphorylation sites have been tentatively mapped to the DNA binding domain only of murine p53 (Milne et al., 1996) , but phosphopeptide analysis of human p53 shows no equivalent phosphopeptides (Milne et al., 1996; and our unpublished data) . (5) Murine p53 is phosphorylated at a single residue by the Jun N-terminal kinases (JNKs) both in vitro and in UV-irradiated cultured cells (Hu et al., 1997; Milne et al., 1995) . Human p53 is phosphorylated at the equivalent site (serine 33) by CDK7-cyclin H-p36 (at least in vitro) (Ko et al., 1997) ; phosphorylation of human p53 by JNK can apparently occur at two as yet unidenti®ed residues (Adler et al., 1997) . (6) Finally, protein kinase CK1 (casein kinase 1) phosphorylates murine p53 at serines 4, 6 and 9 (Knippschild et al., 1997; Milne et al., 1992) ; CK1 also phosphorylates full length human p53 and a GST-fusion protein containing the N-terminal 42 amino acids; however, serines 6 and 9, the equivalent residues to the CK1 phosphorylation sites of murine p53, are not the primary targets of CK1 in human p53 (N Dumaz, D Milne and D Meek, unpublished data) . While, independently, these observations may appear to be minor, taken together they make a strong case for species-speci®c dierences in both the modi®cation, and the regulation, of p53. Therefore the detailed understanding of the induced modi®cations observed in human p53 is not necessarily identical in all other species.
The role of phosphorylation in p53 stabilization and activation: central player, auxiliary backup or opportunistic bystander?
Over the past 10 yrs there have been a variety of studies which have aimed to understand the role of individual phosphorylation events in regulating p53 activity (for recent detailed reviews see Giaccia and Kastan, 1998; Meek, 1997 Meek, , 1998 Prives and Hall, 1999) . While many of these studies have provided evidence supporting a role for modi®cation, others have suggested that p53 function is not impaired by preventing modi®cation of key sites in vivo. For example, mutation of a series of key phosphorylation sites in the N-and C-termini of human p53, including the residues important for blocking the p53-MDM2 interaction and stimulating interaction with 14-3-3, has no eect on the ability of UV or ionizing radiation to induce stabilization of the mutant p53 proteins in cultured cells (Blattner et al., 1999) . Similarly, collective mutation of the N-or C-terminal phosphorylation sites, or all of the known phosphorylation sites simultaneously, shows only subtle eects on stabilization following DNA damage, transcriptional function or interaction with MDM2 (Ashcroft et al., 1999) . In contrast the level of MDM2 has a profound eect on the ability to induce these proteins (Blattner et al., 1999) . Moreover, disruption of the interaction between endogenous p53 and MDM2 proteins in cells expressing only wild type p53 is sucient in itself to stabilize the p53 and elicit a measurable p53 response in terms of activation of a p53-responsive reporter gene and the onset of cell cycle arrest (Bottger et al., 1997) . These studies place heavy emphasis on the central role of MDM2 in governing p53 inhibition and induction, and suggest that any possible role for phosphorylation in the activation mechanism may be super¯uous or redundant. There is also circumstantial evidence consistent with this idea. For example, a number of studies suggest that speci®c modi®cations are not always tightly conserved across species. One might expect important regulatory sites and pathways to operate on a conserved species-wide basis. Moreover, while mutations in p53 occur in a wide variety of human tumours and with very high frequency, mutations at phosphorylation sites are not generally a major event in the development of human disease.
In contrast to these ideas, many studies have tackled the role of phosphorylation and acetylation at the biochemical level and have produced compelling evidence that p53 is activated by key modi®cations. For example, C-terminal phosphorylation at sites targeted by cyclin-dependent protein kinases, protein kinase C, and protein kinase CK2 activate the sitespeci®c DNA binding function of p53 (Delphin and Baudier, 1994; Hupp and Lane, 1994; Hupp et al., 1992; Sakaguchi et al., 1997; Takenaka et al., 1995; Wang and Prives, 1995; Waterman et al., 1998) in¯uence promoter selectivity (Wang and Prives, 1995) , stimulate the interaction with 14-3-3 proteins (Waterman et al., 1998) and stimulate p53-dependent transactivation in vitro (Mundt et al., 1997) . In the case of 14-3-3 binding, the importance of phosphorylation has been further demonstrated in cultured cells. Moreover, the absence of this mechanism in cells from patients with AT highlights its potential relevance to human disease (Waterman et al., 1998) . In vitro analyses have also shown the importance of N-terminal Figure 3 Dierences and similarities in the modi®cation of human and murine p53 proteins. The p53 protein is shown schematically with the known phosphorylation sites in human p53 indicated above the ®gure, and those in murine p53 indicated below the ®gure. Details of these modi®cations are given in the text phosphorylation in MDM2 binding and in promoting C-terminal modi®cation by acetylation Shieh et al., 1997) . Additional lines of evidence underscore the importance of post-translational modi®cation in controlling p53 activity. (1) Multisite phosphorylation and acetylation accompanies induction and activation of p53 by DNA damage and its seems unlikely that evolution has generated such a complex and elaborate series of events without a driving underlying requirement or selective advantage for having this system in place. The multisite, sequential and highly organized nature of these modi®cations underscore this idea. It therefore seems highly unlikely that these modi®cations occur in an opportunistic sense without any speci®c purpose. (2) The modi®cations have a dierent`¯avour' when UV as opposed to IR is the inducing signal, so there is speci®city in the response which possibly re¯ects the need to programme the p53 response to the eects of the particular stimulus. (3) Attempts to assign function to modi®cations in growing cells are based on introducing mutations at key phosphorylation sites, and expressing the mutant proteins, usually at very high levels under strong promoters, in a range of cell types (with variable endogenous p53 status). Overexpression and cellular background may obscure eects of phosphorylation which may be important when p53 is functioning at physiological levels.
In light of these opposing ideas, what are the key factors in regulating p53 and what weight does posttranslational modi®cation carry? The key regulator is unquestionably MDM2 which is targeted by (at least) two well-characterized induction pathways. In the case of oncogene-dependent induction, the mechanism which targets MDM2 involves interaction with the ARF protein. In the case of DNA damage, the targeting molecule is not known, but it is interesting to note that MDM2 is a substrate for DNA-PK (and possibly other related kinases such as ATM and ATR) (Mayo et al., 1997) . Moreover, phosphorylation of MDM2 by DNA-PK is sucient to block its interaction with p53 suggesting that MDM2 could be modi®ed by the same protein kinase(s) as p53 leading perhaps to a cooperative or coordinated dissociation of the p53-MDM2 complex. However, this idea remains to be tested. (It is also interesting to note that Zhang et al. (1998) observed that coexpression of ARF alters the migration properties of MDM2 in SDS ± PAGE, suggesting that ARF might induce p53 through a mechanism involving modi®cation of MDM2). The extensive modi®cations of p53 may yet turn out to have a direct bearing on p53 activation physiologically. Alternatively, modi®cation could play an auxiliary role. For example, there may be redundant mechanisms for inducing p53 by DNA damage: if multisite modi®cation is part of such a system, loss of phosphorylation sites through mutation could bè backed-up' by a dierent mechanism. Modi®cation of p53 could also be a`follow-up' mechanism which prevents re-association with MDM2 and commits p53 to initiating and maintaining downstream events. Moreover, since activation of p53 can have profound or even fatal consequences for an individual cell, the appropriate sequence of modi®cations could be akin to entering the correct combination or code to enable commitment to permanent arrest or cell death. Multisite modi®cation could also act as a ®ne tuning mechanism which adjusts the p53 response in a manner that is appropriate to the type of inducing signal (e.g. UV as compared with IR), the type of cell, the growth status of the cell or the environment in which the cell exists. Probing the function of these modi®cations in vivo is not a trivial exercise and attempts to address this issue having relied heavily on over-expression of mutant proteins with its accompanying caveats. Perhaps one goal of this exercise should be to substitute phosphorylation site mutations for wild type sequences in single copy in transgenic animals to determine whether indeed modi®cation of p53 truly plays an important role in vivo.
